In the paper entitled: Long-term follow-up results in patients undergoing percutaneous coronary intervention with drug-eluting stent, Hai-Mu Yao and colleagues report on a single center all comer DES registry, including 2,735 patients with a median followup of around 30 months. The most striking difference in terms of patient population as compared to an expected all comer PCI population in a western environment pertains to the remarkably low and high number of acute and delayed PCI in STEMI patients, respectively. The reasons for late intervention in this setting are not detailed: late presenters? Attempt to stabilize them with medical therapy first? Did these patients receive lysis before? No information about DES type(s) is reported which is a major limitation for a paper aiming to report the long-term follow-up events after DES implantation. We have learned in the last years that there is DES and DES and as such there is consensus that no class effect should be anticipated for these devices. It is unclear if an independent committee has adjudicated events homogenously. It is unclear how long term medications after PCI were managed. In particular, DAPT duration would have been of particular interest to see. It is unclear how many patients were treated with BMS or perhaps other devices during the recruitment period and what were the reasons for this choice. I would be curious to know if how much this patient population reported here is representative for the country. Predictors of adverse events have been generated in this analysis. The paper is generally well written and clear even if it largely suffers from a lack of novelty.
In the paper entitled: Long-term follow-up results in patients undergoing percutaneous coronary intervention with drug-eluting stent, Hai-Mu Yao and colleagues report on a single center all comer DES registry, including 2,735 patients with a median followup of around 30 months. The most striking difference in terms of patient population as compared to an expected all comer PCI population in a western environment pertains to the remarkably low and high number of acute and delayed PCI in STEMI patients, respectively. The reasons for late intervention in this setting are not detailed: late presenters? Attempt to stabilize them with medical therapy first? Did these patients receive lysis before? No information about DES type(s) is reported which is a major limitation for a paper aiming to report the long-term follow-up events after DES implantation. We have learned in the last years that there is DES and DES and as such there is consensus that no class effect should be anticipated for these devices. It is unclear if an independent committee has adjudicated events homogenously. It is unclear how long term medications after PCI were managed. In particular, DAPT duration would have been of particular interest to see. It is unclear how many patients were treated with BMS or perhaps other devices during the recruitment period and what were the reasons for this choice. I would be curious to know if how much this patient population reported here is representative for the country. Predictors of adverse events have been generated in this analysis. The paper is generally well written and clear even if it largely suffers from a lack of novelty. I suggest to remove the figures since they do not add important messages.
I believe that a drastic manuscript shortening and a better focus on the really useful data will improve the quakity of manuscript.
There are several mistyping and syntax errors in the written english.Please work on it.
REVIEWER
Seung Woon Rha Cardiovascular Center, Korea University Guro Hospital, Seoul, Korea
REVIEW RETURNED

24-Mar-2014
GENERAL COMMENTS
3. While this paper is interesting, there is nothing novel in the drug eluting stent era. This paper reflected the specific state of China. 4. Refence of definition for old age is absent 9. Most important objective in the clinical result is mortality. Independent predictors for mortality is absent in the current paper. DES classification was not addressed 11. Conclusion is not precise. current conclusion is repetition of abstract. Important parameters or predictors associated with DES has to be described. 12. LV systolic functioin in urgent PCI group(STEMI group) is higher compared with that in other registries. Why is the reason ? 15. Most of all, English of this article is far from perfect. English editing is absolutely needed. This is an good study that investigates the impact of DES in real world practice. Although the study is a large volume data reflecting real world practice, there is nothing novel in the DES era and as such is not acceptable.
First, Almost the patients with STEMI received urgent (primary) PCI in most studies. But patients with STEMI with urgent PCI was very small in this sutdy. This paper reflected only the specific state of China.
Second, Most important objective in the clinical result is mortality.
Independent predictors for mortality is absent in the current paper.
In addition, predictor of the occurrence of MACCE was old age in the multivariate analysis. but reference for definition of old age (<65 years) is absent. Importantly, DES classification was not addressed.
Third, curret study is "Long-term follow-up results in patients undergoing percutaneous coronary intervention with drug-eluting stent". However, conclusion was repetition of abstract. Important parameters or predictors associated with DES has to be described.
Lastly, Most of all, English of this article is far from perfect. English editing is absolutely needed.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 In the paper entitled: Long-term follow-up results in patients undergoing percutaneous coronary intervention with drug-eluting stent, Hai-Mu Yao and colleagues report on a single center all comer DES registry, including 2,735 patients with a median follow-up of around 30 months. The most striking difference in terms of patient population as compared to an expected all comer PCI population in a western environment pertains to the remarkably low and high number of acute and delayed PCI in STEMI patients, respectively. The reasons for late intervention in this setting are not detailed: late presenters? Attempt to stabilize them with medical therapy first? Did these patients receive lysis before? Response: Thank you for your insightful comments. China is a developing country now, most population is poor, and many local hospitals could not perform PCI. Most patients from the countryside could not be transferred to a large hospital for PCI within the "time window" of PCI. In addition, cost is another problem. Different from Western countries, in which medical fee was paid by insurance, Chinese patients have to pay about half of their medical fee by themselves, some patients could not afford the money immediately (PCI was expensive and medical environment is not good in China). Furthermore, thrombolytic therapy is relatively cheaper and it could be started immediately at local hospital. So, most patients received thrombolytic therapy first at a local hospital (if there were no contraindications). Of course, there are also some late presenters and those who were not suitable for thrombolytic therapy, just stabilizing them with medical therapy first. No information about DES type(s) is reported which is a major limitation for a paper aiming to report the long-term follow-up events after DES implantation. We have learned in the last years that there is DES and DES and as such there is consensus that no class effect should be anticipated for these devices. Response: It has been provided in our revised manuscript. It is unclear if an independent committee has adjudicated events homogenously. Response: We have an independent committee to adjudicate the events and we have noted this in our revised manuscript. It is unclear how long term medications after PCI were managed. In particular, DAPT duration would have been of particular interest to see. Response: It has been noted in our revised manuscript. In our center, all patients were prescribed 100 mg/d aspirin indefinitely and clopidogrel 75 mg/d for at least the first 12 months after the procedure, and all patients were advised to maintain statin lifelong unless there were contraindications. There were 13 patients temporarily discontinued one or both of the two antiplatelet drugs. Reasons for discontinuation were bleeding in 5 patients and unexpected surgery in 8 patients, but all of these patients were not suffered from stent thrombosis. Due to the discontinuation was short and there was no stent thrombosis occurred, we didn't note it in the article. It is unclear how many patients were treated with BMS or perhaps other devices during the recruitment period and what were the reasons for this choice. Response: Thank you for your question. In our center, almost all the patients were implanted with DES. During the recruitment period, there were only four patients implanted with eight BMS. Of them, one patient was due to the coronary artery dilatation, there was no appropriate DES for the lesion; two patients were because of combined malignancy disease, and another one patient was due to combined disease which needed operation. I would be curious to know if how much this patient population reported here is representative for the country. Predictors of adverse events have been generated in this analysis. The paper is generally well written and clear even if it largely suffers from a lack of novelty. Response: Thank you for your encouragement and insightful comments. Henan is the most populous province of China, which has a population of nearly one hundred million. It is located in the central part of China, with the middle level of economic development. Our hospital is the largest comprehensive teaching hospital in china. There are six wards, over 250 beds, and 5 interventional operation rooms in our center. Most of our patients were from Henan province, and there were also some patients from adjacent province. Different from other hospitals in the big city (eg, Beijing and Shanghai), over 60% of our patients were from the countryside. As you know, in a big country like China, there was no single-center patient population could completely represent the country. In contrast, our patient population has a more extensive representativeness. Moreover, data of registries on long-term follow-up from the Chinese population were sparse. So it is worthy of conducting the study.
Reviewer: 2 I would suggest to split the study population in only three groups: STEMI (urgent and delayed),stable angina and STEACS.to make clear what the Authors want to demonstrate. Response: Thank you for your kind suggestions. We divided the study population into four groups because most patients with STEMI received delayed PCI in our study. Different from most Western studies, there were only about 16% patients with STEMI received urgent PCI in our study. It is well known that patients with urgent PCI experienced higher clinical events. If we grouped patients with urgent and delayed PCI together, it may underestimate the clinical events rate. In addition, there were many patients with STEMI received delayed PCI in China, we also wanted to observe the safety and efficacy of the delayed PCI. The results section, the Discussion section, the Abstract, the Tables are too long or too much Response: Thank you for your comments. According to your suggestion, in our revised manuscript we have made corresponding revision The manuscript must be reduced at least of 40% to make it clear to the reader Response: Thank you for your critical comments and insightful suggestions. In our revised manuscript we have made corresponding revision Use only paramount baseline and long term FU data. Response: Thank you for your kind suggestions. In our revised manuscript we have deleted unimportant baseline data. I suggest to remove the figures since they do not add important messages. I believe that a drastic manuscript shortening and a better focus on the really useful data will improve the quality of manuscript. Response: Thank you for your kind suggestions. According to your advice, in our revised manuscript we have removed the figures and shorten the manuscript. There are several mistyping and syntax errors in the written English. Please work on it Response: Thank you for your kind comments. It has been corrected in our revised manuscript, and the revised manuscript has been checked and edited by the Bioedit English editing service.
Reviewer: 3 3. While this paper is interesting, there is nothing novel in the drug eluting stent era. This paper reflected the specific state of China. Response: Henan is the most populous province of China, which has a population of nearly one hundred million. It is located in the central part of China, with the middle level of economic development. Our hospital is the largest comprehensive teaching hospital in China. There are 6 wards, over 250 beds, and 5 interventional operation rooms in our center. As you know, in a big country like China, there was not any single-center patient population could completely represent the country. In contrast, our patient population has a more extensive representativeness. Moreover, data from registries on long-term follow-up in Chinese population were sparse. So it is worth conducting the study. 4. Refence of definition for old age is absent Response: Thank you for your kind comments. We defined patients ≥ 65 years old as being older age （refer to the InChIANTI study）[Laudisio A, Bandinelli S, Gemma A, Ferrucci L, Antonelli Incalzi R.
Metabolic syndrome and hemoglobin levels in elderly adults: the Invecchiare in Chianti study]. In order to make the adjustments in the Cox model more rigorous, age have been analyzed as continuous variables in the Cox model in our revised manuscript. 9. Most important objective in the clinical result is mortality. Independent predictors for mortality is absent in the current paper. DES classification was not addressed Response: Thank you for your kind comments. It has been added in our revised manuscript 11. Conclusion is not precise. current conclusion is repetition of abstract. Important parameters or predictors associated with DES has to be described. Response: Thank you for your insightful comments. In our revised manuscript We have made corresponding revision 12. LV systolic functioin in urgent PCI group(STEMI group) is higher compared with that in other registries. Why is the reason ? Response: In our study, LVEF was determined by echocardiography. Patients with urgent PCI echocardiography were performed just before discharge. Not all of the patients had done echocardiography during admission. We checked our data carefully. There were a total of 1600 patients with the results of echocardiography, and in urgent PCI group, there were only 35(35.4%) patients with the results of echocardiography, which might miss those lower LV systolic functional patients. This might be the main reason. In addition, different measurement time might also affect the results. We have noticed that there were difference in different studies with respect to LV systolic function (eg, in Sciences. 2011; 56:222-230") . So, LV systolic function might be affected by multi-factor. To be honest, we could not make clear of the exact reason based on the current data. 15. Most of all, English of this article is far from perfect. English editing is absolutely needed. Response: Thank you for your kind comments. It has been corrected in our revised manuscript, and the revised manuscript has been checked and edited by the Bioedit English editing service. This is an good study that investigates the impact of DES in real world practice. Although the study is a large volume data reflecting real world practice, there is nothing novel in the DES era and as such is not acceptable. Response: Thank you for your encouragement and insightful comments. Henan is the most populous province of China, which has a population of nearly one hundred million. It located in the central part of China, with the middle level of economic development. Our hospital is the largest comprehensive teaching hospital in China. There are six wards, over 250 beds, and 5 interventional operation rooms in our center. Most of our patients were from Henan province, and there were also some patients from adjacent province. In contrast, our patient population was more extensive representativeness. Although there were many register studies about DES, data from registries on long-term follow-up in Chinese population were sparse. So it is worth of conducting the study.
First, Almost the patients with STEMI received urgent (primary) PCI in most studies. But patients with STEMI with urgent PCI was very small in this sutdy. This paper reflected only the specific state of China. Response: Thank you for your insightful comments. China is a developing country now, people is relatively poor, and many local hospitals could not perform PCI. Most patients from countryside could not be transferred to big hospital within the "time window" of PCI. In addition, cost is another problem. Different from western countries in which medical fee was paid by insurance, Chinese patients have to pay about half of the medical fee by themselves, some patients could not afford the money immediately (PCI was expensive and medical environment is not good in china). Furthermore, thrombolytic therapy is relatively cheap and could start immediately at local hospital. So, most patients received thrombolytic therapy first at local hospital (if there were no contraindications). Of course, there are also some late presenters and those who were not suitable for thrombolytic therapy, just stabilizing them with medical therapy first. Henan is the most populous province of China, which has a population of nearly one hundred million. It located in the central part of china, with the middle level of economic development. Our hospital is the largest comprehensive teaching hospital in China. There are six wards, over 250 beds, and 5 interventional operation rooms in our center. Most of our patients were from Henan province, and there were also some patients from adjacent province. Different from other hospital in big city (eg, Beijing and Shanghai), over 60% of our patients were from countryside. As you know, in a big country like China, there was not any single-center patient population could completely represent for the country. In contrast, our patient population has a more extensive representativeness. Although there were many register studies about DES, data from registry on long-term follow-up in Chinese population were sparse. So it is worthy of conducting the study. Second, Most important objective in the clinical result is mortality. Independent predictors for mortality is absent in the current paper. In addition, predictor of the occurrence of MACCE was old age in the multivariate analysis. but reference for definition of old age (<65 years) is absent. Importantly, DES classification was not addressed. Response: Thank you for your kind suggestions and insightful comments. These have been provided in our revised manuscript. In addition, we defined patients ≥ 65 years old as being older age（refer to the InChIANTI study）[Laudisio A, Bandinelli S, Gemma A, Ferrucci L, Antonelli Incalzi R. Metabolic syndrome and hemoglobin levels in elderly adults: the Invecchiare in Chianti study]. In order to make the adjustments in the Cox model more rigorous, age have been analyzed as continuous variables in the Cox model in our revised manuscript. Third, current study is "Long-term follow-up results in patients undergoing per-cutaneous coronary intervention with drug-eluting stent". However, conclusion was repetition of abstract. Important parameters or predictors associated with DES has to be described. Response: Thank you for your comments. In our revised manuscript, we have change it in our revised manuscript.
VERSION 2 -REVIEW
REVIEWER
Marco Valgimigli Erasmus MC The Netherlands
REVIEW RETURNED
11-May-2014
GENERAL COMMENTS
"This is a meticulous assessment of outcomes after first generation DES out of a single center experience. My decision to advise for a reject is based on two major concerns regarding this paper: 1) First generation DES are not available on the market anymore and therefore, this is in a way historical data which cannot inform present decision making.
2) The literature is indeed full of single center reports like this one and this paper, as I pointed out during my first revision, dos not add basically much to the existing evidence. 
13-May-2014
GENERAL COMMENTS
This is an good study that investigates the impact of DES in real world practice. Although the study is a large volume data reflecting real practice in China, there is nothing novel in the DES era and as such is not acceptable. First, curret study is "Long-term follow-up results in patients undergoing percutaneous coronary intervention with drug-eluting stent". However, implanted DES was 1st generation DES(SES and PES). Recently, 2nd generation DES was widely used in most patients receiving PCI. This paper did not exactly reflected real world practice and clinical outcomes. Second, in the clinical characteristics, proportion of patients presenting cardiogenic shock was too small. Did authors omit these patients(did not undergoing PCI) in the registry ? Third, authors had described already, echocardiography was performed in small study population. Therefore, parameter of LV systolic function in patients with STEMI with urgent PCI was not reliable. These problem should be added in the limitation. Lastly, English of this article is still far from perfect. English editing is absolutely needed.
Reviewer: 1 "This is a meticulous assessment of outcomes after first generation DES out of a single center experience. My decision to advise for a reject is based on two major concerns regarding this paper: 1) First generation DES are not available on the market anymore and therefore, this is in a way historical data which cannot inform present decision making. Response: Thank you for critical comments. The patients receive the 1st generation DES in our study. But it is still meaningful for present decision making. Although 2nd generation DES has some improvements, there are no fundamental changes, and few studies have evaluated its long-term outcomes. Our study could be as a reference to evaluate the long-term clinical outcomes of 2nd generation DES. Additionally, the advances in interventional cardiology and drugs contribute to the improvement of CAD therapy results, which made it necessary to perform a periodical assessment of the treatments.
2) The literature is indeed full of single center reports like this one and this paper, as I pointed out during my first revision, dos not add basically much to the existing evidence. Therefore, I am prone to advise against its acceptance. But this is of course only my opinion. " Response: Although there are some studies about DES, data from registries on long-term follow-up in the Chinese patients are sparse. As a real-world study, our study has some advantages: 1) almost all patients receive DES in our center, it reflects the clinical practice in China; 2) over 95% PCI process is performed through radial artery access; 3) different from other studies in which most patients with AMI received urgent PCI, there is a certain amount of patients received delayed PCI in our study; 4) just as discussed in our manuscript, we have to take economic status into consideration when we evaluated some endpoints (such as revascularization) , just because of China is a developing country.
Reviewer: 3 This is an good study that investigates the impact of DES in real world practice. Although the study is a large volume data reflecting real practice in China, there is nothing novel in the DES era and as such is not acceptable. Response: As a real-world study, our study has some novel characteristics: 1), almost all patients receive DES in our center, it reflected the clinical practice in China; 2) over 95% PCI process is performed through radial artery access; 3) different from other studies in which most patients with AMI received urgent PCI, there is a certain amount of patients received delayed PCI in our study; 4) just as discussed in our manuscript, we have to take economic status into consideration when we evaluated some endpoints (such as revascularization) , just because of China is a developing country First, current study is "Long-term follow-up results in patients undergoing percutaneous coronary intervention with drug-eluting stent". However, implanted DES was 1st generation DES(SES and PES). Recently, 2nd generation DES was widely used in most patients receiving PCI. This paper did not exactly reflected real world practice and clinical outcomes. Response: Just as you said, from the view of stent, our study indeed does not exactly reflect current real world practice and clinical outcomes, we have added this as a limitation in our revised manuscript. But it is still useful for the physician. Although 2nd generation DES has some improvements, there are no fundamental changes, and few studies have evaluated its long-term outcomes. Our study could be as a reference to evaluate the long-term clinical outcomes of 2nd generation DES. Additionally, the advances in interventional cardiology and drugs contribute to the improvement of CAD therapy results, which made it necessary to perform a periodical assessment of the treatments.
Second, in the clinical characteristics, proportion of patients presenting cardiogenic shock was too small. Did authors omit these patients(did not undergoing PCI) in the registry ? Response: Thank you for your question. Indeed, the proportion of patients presenting cardiogenic shock was very small in our study. This is a registry study regarding to PCI. Patients who did not undergo PCI were not included in the study. Third, authors had described already, echocardiography was performed in small study population. Therefore, parameter of LV systolic function in patients with STEMI with urgent PCI was not reliable. These problem should be added in the limitation. Response: According to your advice, we have added these in the limitation section in our revised manuscript.
Lastly, English of this article is still far from perfect. English editing is absolutely needed. Response: Thank you for your kind comments. The revised manuscript has been checked and edited by the Bioedit English editing service again (https://www.bioedit.com/). 
16-Jun-2014
GENERAL COMMENTS
My decision to reject revised paper is based on major concerns regarding this paper: First, although authors argued that there were no fundamental changes between 1st and 2nd drug eluting stent (DES), DES was evolved significantly. As authors have known, there was significant difference in stent strut, polymer, cytotoxic drug between 1st and 2nd DES. Currently, 2nd generation DES was widely used in most patients receiving PCI. This paper did not exactly reflect real world practice and clinical outcomes. Second, these data as registry study was very weak. There were no unique educational messages, few primary PCI rate, low rate of echocardiographic data. Lastly, English of this article is still far from perfect. English editing is absolutely needed.
VERSION 3 -AUTHOR RESPONSE
Reviewer: 3 First, although authors argued that there were no fundamental changes between 1st and 2nd drug eluting stent (DES), DES was evolved significantly. As authors have known, there was significant difference in stent strut, polymer, cytotoxic drug between 1st and 2nd DES. Currently, 2nd generation DES was widely used in most patients receiving PCI. This paper did not exactly reflect real world practice and clinical outcomes. Response: As you said, DES is evolved significantly. In fact, we keep pace with the international centers, using the newest stent and technology. In order to facilitate the description, we simply divided patients into two categories: SES or PES. Of course, some types of stents have stopped production (eg., cypher ), and some new stents have been used widely (eg., XIENCE V). From this point, our study did not exactly reflect real world practice and clinical outcomes. We have made appropriate explanation and added this as a limitation in our revised manuscript. Second, these data as registry study was very weak. There were no unique educational messages, few primary PCI rate, low rate of echocardiographic data. Response: In fact, the low primary PCI rate just reflects the clinical practice in China, and this is one aspect which is different from previous studies. The rate of echocardiographic data is low in patients with STEMI, because most patients do this at local hospital. Considering the cost and accuracy of echocardiographic data, we didn't repeat this procedure in our hospital. But in other patients, most patients have the echocardiographic data. We have added this as a limitation in our revised manuscript. Lastly, English of this article is still far from perfect. English editing is absolutely needed. Response: Thank you for your kind comments. We have checked and edited our manuscript carefully again.
